Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,476 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin-Dependent Diabetes Mellitus 1 Clear all
Terminated Not applicable Interventional

Glucagon Counterregulation in Type 1 Diabetes

NCT03547427
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Phase 4 Interventional

Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes

NCT02019186
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Vitamin C, Vitamin E
Dietary Supplement
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
8 Years to 15 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 15, 2026, 4:26 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Diabetes Inspired Culinary Education (DICE): Culinary Medicine Intervention for At-Risk Youth With Type 1 Diabetes

NCT07084805
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Diabetes Inspired Culinary Education (DICE) - Phase 1, Diabetes Inspired Culinary Education (DICE) - Phase 2
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
8 Years to 14 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

NCT01986231
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 15, 2026, 4:26 AM EDT
Completed No phase listed Observational

Description of Patients With Type 1 Diabetes Treated With Teplizumab

NCT06892002
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teplizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
24
States / cities
Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 15, 2026, 4:26 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

NCT00322257
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
inhaled human insulin, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Concord, California + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 15, 2026, 4:26 AM EDT
Enrolling by invitation Not applicable Interventional

Sleep Screening and Intervention for Adolescents With Type 1 Diabetes in a Clinical Diabetes Center

NCT07494188
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sleep intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
11 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes

NCT06098729
View directory record Official record
Conditions
Type 1 Diabetes, Latent Autoimmune Diabetes in Adults, Pancreatitis
Interventions
Digital Exercise
Behavioral
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Not applicable Interventional

Virtual Physical Activity for Type 1 Diabetes

NCT05163912
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Virtual home intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 19 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 15, 2026, 4:26 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes

NCT04164966
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
12 Years to 18 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

Overcoming Barriers and Obstacles to Adopting Diabetes Devices

NCT04161131
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ONBOARD
Behavioral
Lead sponsor
Molly Tanenbaum
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

NCT05378672
View directory record Official record
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
Up to 5 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Phase 4 Interventional Results available

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

NCT00442767
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Pramlintide + Insulin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 15, 2026, 4:26 AM EDT
Recruiting Phase 2 Interventional

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

NCT05762107
View directory record Official record
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg
Drug
Lead sponsor
Zucara Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
38
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 15, 2026, 4:26 AM EDT
Terminated Phase 1 Interventional

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

NCT01216436
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination with RNA-transfected mature autologous DC
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)

NCT03263494
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
14 Years to 24 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

NCT00046501
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
9 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Phase 4 Interventional Results available

Afrezza® Dosing Optimization Study

NCT04849845
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Afrezza Dose 1, Afrezza Dose 2
Combination Product
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Escondido, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 15, 2026, 4:26 AM EDT
Not listed Phase 1Phase 2 Interventional

hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure

NCT00008801
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Experimental, Transplantation, Homologous, Islets of Langerhans Transplantation
Interventions
hOKT3gamma1 (Ala-ala)
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2005 · Synced Oct 15, 2026, 4:26 AM EDT
Not listed Not applicable Interventional

Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features

NCT05131139
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
14 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Escondido, California • Idaho Falls, Idaho • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Not applicable Interventional

Integrated Behavioral Healthcare for Youth With Type 1 Diabetes

NCT05915975
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Behavioral Care Coordinated with Medical Care Intervention, Behavioral Care Not Coordinated with Medical Care Intervention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 15, 2026, 4:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

NCT05791201
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
VX-264
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 4:26 AM EDT
Completed No phase listed Observational

The Influence of Non-Caloric Artificial Sweeteners on Youth With Type 1 Diabetes

NCT03889522
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Bioelectrical Impedance Analysis, Total Body Dual-energy X-ray Absorptiometry, Blood draw
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 15, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

NCT01445951
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Burlingame, California • Escondido, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 15, 2026, 4:26 AM EDT